Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK584449PMID: 36153937
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 1340593-59-0
Drug Levels and Effects
Summary of Use during Lactation
Oteseconazole must not be used by women of reproductive potential because of the possibility of fetal harm. It is extremely long-lasting and could remain in the milk for as long as 2 years after a course of therapy. An alternate drug should be used.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
Substance Identification
Substance Name
Oteseconazole
CAS Registry Number
1340593-59-0
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- "Efficacy and safety of oteseconazole in recurrent vulvovaginal candidiasis (RVVC) - A systematic review and meta-analysis".[Heliyon. 2023]"Efficacy and safety of oteseconazole in recurrent vulvovaginal candidiasis (RVVC) - A systematic review and meta-analysis".Siddiqui T, Kumar KA, Iqbal A, Doultani PR, Ashraf T, Eqbal F, Siddiqui SI. Heliyon. 2023 Nov; 9(11):e20495. Epub 2023 Oct 20.
- Review Oteseconazole: a long-awaited diversification of the antifungal arsenal to manage recurrent vulvovaginal candidiasis (RVVC).[Expert Rev Anti Infect Ther. 2...]Review Oteseconazole: a long-awaited diversification of the antifungal arsenal to manage recurrent vulvovaginal candidiasis (RVVC).Vandecruys P, Baldewijns S, Sillen M, Van Genechten W, Van Dijck P. Expert Rev Anti Infect Ther. 2023 Jul-Dec; 21(8):799-812. Epub 2023 Jul 24.
- Oteseconazole (Vivjoa) for recurrent vulvovaginal candidiasis.[Med Lett Drugs Ther. 2022]Oteseconazole (Vivjoa) for recurrent vulvovaginal candidiasis.. Med Lett Drugs Ther. 2022 Aug 8; 64(1656):124-126.
- Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections.[Am J Obstet Gynecol. 2022]Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections.Martens MG, Maximos B, Degenhardt T, Person K, Curelop S, Ghannoum M, Flynt A, Brand SR. Am J Obstet Gynecol. 2022 Dec; 227(6):880.e1-880.e11. Epub 2022 Jul 19.
- Review Oteseconazole: First Approval.[Drugs. 2022]Review Oteseconazole: First Approval.Hoy SM. Drugs. 2022 Jun; 82(9):1017-1023.
- Oteseconazole - Drugs and Lactation Database (LactMed®)Oteseconazole - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...